BRAF and differentiated thyroid carcinoma: However, this possibility is refuted by the treatment response of both pleural metastasis of papillary thyroid carcinoma and lung tumours of NSCLC to dabrafenib and trametinib combination therapy targeting BRAF V600E mutated tumour.